Academic Journal
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines
| العنوان: | Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines |
|---|---|
| المؤلفون: | Mortensen, Martin Bødtker, Tybjærg-Hansen, Anne, Nordestgaard, Børge G |
| المصدر: | Mortensen , M B , Tybjærg-Hansen , A & Nordestgaard , B G 2022 , ' Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines ' , JAMA cardiology , vol. 7 , no. 8 , pp. 836-843 . https://doi.org/10.1001/jamacardio.2022.1876 |
| سنة النشر: | 2022 |
| المجموعة: | Aarhus University: Research |
| مصطلحات موضوعية: | 10-YEAR RISK, AMERICAN-COLLEGE, ASSOCIATION TASK-FORCE, CLINICAL-PRACTICE, RISK THRESHOLDS, SCORE, SOCIETIES, THERAPY, VALIDATION |
| الوصف: | Importance: For primary prevention of atherosclerotic cardiovascular disease (ASCVD), the 2021 European Society of Cardiology (ESC) guidelines on statin use (hereafter European-ESC) recommend a new risk model (Systematic Coronary Risk Evaluation 2 [European-SCORE2]) as well as new age-specific treatment thresholds (≥7.5% 10-year ASCVD risk if aged 40-49 years and ≥10% if aged 50-69 years). Objective: To compare the clinical performance of the 2021 European-ESC, American College of Cardiology/American Heart Association (hereafter US-ACC/AHA), UK National Institute for Health and Care Excellence (UK-NICE), and 2019 ESC/European Atherosclerosis Society (EAS) guidelines in apparently healthy individuals. Design, Setting, and Participants: This population-based contemporary cohort study included 66 909 individuals from the Copenhagen General Population Study. Participants were aged 40 to 69 years and were free of ASCVD, diabetes, chronic kidney disease, and statin use at baseline in 2003 to 2015. Mean follow-up time was 9.2 years. Data were analyzed from November 2021 to April 2022. Exposures: Statin treatment according to guideline criteria. Main Outcomes and Measures: Calibration of risk calculators, statin eligibility, sensitivity, and specificity for ASCVD events according to guideline criteria. Results: During follow-up, a range of 2962 to 4277 nonfatal and fatal ASCVD events was observed, as defined by the 2021 European-SCORE2, US pooled cohort equations (PCE), and UK-QRISK3 models, and 180 fatal ASCVD events were noted as defined by the 2019 European-SCORE1 model. European-SCORE2 was slightly better calibrated with a predicted/observed ASCVD event ratio of 0.8 vs 1.3 for US-PCE, 1.3 for UK-QRISK3, and 5.8 for European-SCORE1. For primary prevention class I recommendations in individuals aged 40 to 69 years, 2862 of 66 909 (4%) qualified for statins according to the 2021 European-ESC guidelines compared with 23 029 (34%) with US-ACC/AHA, 17 659 (26%) with UK-NICE, and 13 496 (20%) with 2019 European-ESC/EAS ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1001/jamacardio.2022.1876 |
| الاتاحة: | https://pure.au.dk/portal/en/publications/d944fb3d-cf4a-4d2e-b750-7fe724bfc141 https://doi.org/10.1001/jamacardio.2022.1876 http://www.scopus.com/inward/record.url?scp=85133964851&partnerID=8YFLogxK https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260641/?report=printable |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8485B9DE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamacardio.2022.1876 |
|---|